Thank you for Subscribing to Life Science Review Weekly Brief
This holistically integrated methodology from the partnership will streamline drug discovery pipelines and reduce time to a clinic for firms with challenging targets by facilitating target and structural validation efficiently and cost-effectively.
FREMONT, CA: To develop a streamlined, cryoEM (Cryogenic electron microscopy) enabled gene-to-structure workflow, to ultimately accelerate medicinal chemistry analysis, NanoImaging Services, the premier industry provider of cryoEM services, microscope access and training, and Viva Biotech Holdings, a leading open-access, and innovation-driven technology platform company, have come together for a partnership agreement.
Giovanna Scapin, Ph.D., Chief Scientific Officer at NanoImaging Services, said, “One of the strongest predictors of success in structural enablement of drug discovery targets is the purity, homogeneity, and in-depth biochemical and biophysical characterization of the reagents involved. This agreement utilizes our industry-leading expertise and innovation in high-resolution structural enablement by cryoEM, partnered with a worldwide leader in protein production and characterization. Together we aim to successfully target the most complex and challenging projects in drug discovery for our shared clients in a cost- and time- effective manner.”
This strategic partnership will combine NanoImaging Services’ industry-leading expertise and innovation in cryoEM-based high-resolution structural enablement with Viva Biotech’s world-leading drug discovery platform to allow project management from construct design to final maps and subsequent protein supply, as well as analyses for medicinal chemistry cycles. This holistically integrated methodology will streamline drug discovery pipelines and reduce time to a clinic for firms with challenging targets by facilitating target and structural validation efficiently and cost-effectively.
“We are very excited to build the strategic cooperation with NanoImaging Services,” said Dr. Ren Delin, Executive Director and President of Viva. “NanoImaging Services, the world’s top cryoEM service provider, has considerable advantages in technology and equipment. As the world’s leading drug discovery platform, Viva has efficient protein purification and production capabilities, along with the advanced membrane protein expression and screening technology. Our cooperation is expected to further enhance the ability of target discovery, to empower the clients to develop new drugs as soon as possible, and benefit more patients.”
Target enablement and medicinal chemistry timeframes can be significantly decreased by joining forces and aligning these already established and proven workflows. This, combined with higher success rates, can help reduce overall investment costs and streamline operations.